Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Human Genome Sciences, Inc. (HGSI) -- Ignore unavailable to you. Want to Upgrade?

To: NewsTrader who wrote (230)	10/6/1998 1:23:00 PM
From: Steven Rachbach	Read Replies (1) \| Respond to of 1127

Testing is proceeding at HGSI. Phase 1 testing is in the analysis stage for KGF-2 (Keritinocyte Growth Factor) for the indication of mucositis. Either MPIF-1 (Myeloid Progenitor Inhibitory Factor) or KGF-2 (for the topical treatment of wounds, etc.) will be advanced to Phase II trial by the end of 1998 according to the company spokesperson I talked to last week. VEGF (which stimulates the generation of blood vessels) is also on track to begin testing. HGSI has also now applied for over 2000 gene patents. In the animal studies, MPIF-1 was given both the day before and the day after chemotherapy and seemed to shield the animals from the devastating effects of chemotherapy on blood cells. Often, chemotherapy will wipe out blood cells to the point that the body is open to serious infection (loss of white blood cells) and serious internal hemorrhage (loss of platelets). If MPIF-1 works in humans without serious side-effects, it would be a huge advance in the field of Oncology. If KGF-2 works in the treatment of wounds, burns, mucositis and possibly other illnesses involving epithelial cell destruction (such as inflammatory bowel disease), this drug could have a large market. In addition, Joint Ventures involving the development of vaccines and drugs using HGSI's patents of staphylococcus and enterococcus bacteria are quite promising. Finally, even if the first two drugs don't pan out, there will be possibly hundreds in the future. I believe that the first successful Phase II trial for one of its drugs will catapault HGSI into the spotlight and the rush to buy this stock will be tremendous. Any comments?